Загрузка...
Ipilimumab in prostate cancer
INTRODUCTION: Immune checkpoint inhibitors, such as ipilimumab, are a new class of immunotherapeutic agents that have shown significant efficacy in melanoma. A number of ongoing clinical trials are investigating the role of ipilimumab in prostate cancer, either alone or in combination with immunomod...
Сохранить в:
| Опубликовано в: : | Expert Opin Biol Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628899/ https://ncbi.nlm.nih.gov/pubmed/23265575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2012.754421 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|